Risk prediction tools for cancer in primary care
- PMID: 26633558
- PMCID: PMC4701999
- DOI: 10.1038/bjc.2015.409
Risk prediction tools for cancer in primary care
Abstract
Numerous risk tools are now available, which predict either current or future risk of a cancer diagnosis. In theory, these tools have the potential to improve patient outcomes through enhancing the consistency and quality of clinical decision-making, facilitating equitable and cost-effective distribution of finite resources such as screening tests or preventive interventions, and encouraging behaviour change. These potential uses have been recognised by the National Cancer Institute as an 'area of extraordinary opportunity' and an increasing number of risk prediction models continue to be developed. The data on predictive utility (discrimination and calibration) of these models suggest that some have potential for clinical application; however, the focus on implementation and impact is much more recent and there remains considerable uncertainty about their clinical utility and how to implement them in order to maximise benefits and minimise harms such as over-medicalisation, anxiety and false reassurance. If the potential benefits of risk prediction models are to be realised in clinical practice, further validation of the underlying risk models and research to assess the acceptability, clinical impact and economic implications of incorporating them in practice are needed.
Conflict of interest statement
WH has had many research grants relating to cancer diagnostics from non-commercial sources and has been involved in developing a number of cancer risk prediction tools for use in primary care. He was the clinical lead for the revision of the NICE 2005 guidance (NG12) on the topic of selection of patients for cancer investigation. His contribution to this article is in a personal capacity and should not to be interpreted as representing the view of the Guideline Development Group or NICE. He has received travel support to give lectures and attend conferences, plus occasional speaker's fees, from conference organisers in the charitable and educational sector, although none from commercial sources. SJG developed and evaluated the Cambridge diabetes risk score, which is freely available. He has evaluated the predictive utility of diabetes and cardiovascular disease risk scores. JE has received travel support to give lectures and attend conferences, plus occasional speaker's fees, from conference organisers in the charitable and educational sector, although none from commercial sources. He received consultancy fees from AP Benson Ltd from 2000–2004 relating to the GRAIDS and Cyrillic software. JUS and FMW have no competing interests to declare.
References
-
- Colditz G A, Atwood KA, Emmons K, Monson RR, Willett WC, Trichopoulos D, Hunter DJ (2000) Harvard report on cancer prevention volume 4: Harvard Cancer Risk Index. Risk Index Working Group, Harvard Center for Cancer Prevention. Cancer Causes Control 11: 477–488. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources